Table 4.
Clinical Outcomes Among Contrast‐Induced Nephropathy Risk Groups
| Clinical Events | Overall (n = 1041) | Low (n = 596) | Moderate (n = 265) | High (n = 111) | Very High (n = 69) | P Value |
|---|---|---|---|---|---|---|
| MACCE at 1‐month follow‐up | 53 (5.1%) | 13 (2.2%) | 9 (3.4%) | 12 (12.6%) | 19 (27.5%) | <0.001 |
| Death, all‐cause | 43 (4.1%) | 5 (0.8%) | 8 (3.0%) | 12 (10.8%) | 18 (26.1%) | <0.001 |
| Reinfarction | 6 (0.6%) | 4 (0.7%) | 1 (0.4%) | 0 (0.0%) | 1 (1.4%) | 0.574 |
| TVR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Heart failurea | 1 (0.1%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Cerebrovascular events | 3 (0.3%) | 3 (0.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0.749 |
| MACCE at 2‐year follow‐up | 166 (15.9%) | 66 (11.1%) | 42 (15.8%) | 29 (26.1%) | 29 (42.0%) | <0.001 |
| Death, all‐cause | 84 (8.1%) | 14 (2.3%) | 23 (8.7%) | 22 (19.8%) | 25 (36.2%) | <0.001 |
| Reinfarction | 25 (2.4%) | 15 (2.5%) | 6 (2.3%) | 1 (0.9%) | 3 (4.3%) | 0.518 |
| TVR | 31 (3.0%) | 20 (3.4%) | 8 (3.0%) | 2 (1.8%) | 1 (1.4%) | 0.867 |
| Heart failurea | 15 (1.4%) | 10 (1.7%) | 2 (0.8%) | 3 (2.7%) | 0 (0.0%) | 0.355 |
| Cerebrovascular events | 11 (1.1%) | 7 (1.2%) | 3 (1.1%) | 1 (0.9%) | 0 (0.0%) | 1.000 |
Abbreviations: MACCE, major adverse cardiovascular and cerebrovascular events; TVR, target vessel revascularization.
a
Heart failure requiring hospitalization.